UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~February~~March 319, 2026

Caring Brands, Inc.

(Exact name of registrant as specified in its charter)

Nevada

001-42941

99-4103908

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

130 S Indian River Drive,

Suite 202 pbm# 1232,

Fort Pierce, FL 34950

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (561) 896-7616

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Common Stock, par value $0.001 per share	CABR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 81.01 ~~Other~~Entry ~~Events.~~into a Material Definitive Agreement.

On ~~January~~March 219, 2026, Caring Brands, Inc. (the “Company”), entered into a ~~Nevada~~Securities ~~corporation~~Purchase Agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Purchaser”) for a private investment in public equity (the “PIPE Offering”) of 3,789,474 shares of its Series A Convertible Preferred Stock par value $0.001 per share, stated value $3,789,474 per share (the “~~Company~~Series A Preferred Stock”), ~~issued~~equating to 3,789.74 Series A Convertible Preferred Shares which equates to a ~~press~~purchase ~~release~~price ~~announcing~~of $950 per share of Series A Preferred Stock with a stated value of $1,000 per share, after factoring in an original issue discount (“OID”) of 5%. The Series A Preferred Stock is convertible into common stock.at a conversion price of $0.40 per share. The Company also issued an aggregate of 9,473,685 warrants (the “Common Warrants”) to acquire up to 9,473,685 shares of Common Stock at ~~issuance~~an exercise price of ~~two~~$0.40 ~~new~~per ~~United~~share. ~~States~~The ~~patents~~Common ~~covering~~Warrants ~~proprietary~~issued ~~methods~~in the PIPE Offering are exercisable immediately and ~~compositions~~will ~~designed~~expire five years from the date of issuance. The exercise of the Common Warrants and the conversion of the Series A Preferred Stock are both subject to ~~enhance~~beneficial ~~enzymatic~~ownership ~~activity~~limitations inset ~~hair~~by the holder. The aggregate purchase ~~follicles~~price was $3,600,000. ~~further~~In ~~strengthening~~addition, the Company’s ~~intellectual~~will ~~property~~not ~~portfolio~~issue ~~supporting~~any ~~its~~shares ~~Hair~~upon ~~Enzyme~~the ~~Booster~~exercise ~~product~~of ~~and related~~the ~~matters.~~Warrants Aor ~~copy~~the conversion of the ~~press~~Series ~~release~~A isPreferred ~~filed~~Stock asto ~~Exhibit~~the 99extent that the aggregate issuances thereunder would exceed an aggregate of 19.199% toof ~~this~~the ~~Current~~Company’s ~~Report~~outstanding ~~and~~shares ~~incorporated~~of ~~herein~~common bystock ~~reference~~without first obtaining shareholder approval.

The PIPE Offering closed on March 19, 2026, with aggregate gross proceeds totaling approximately $3.6 million. The Company intends to use $3.075 million of the net proceeds from the PIPE Offering to retire an aggregate of 6,250,000 shares of the Company’s Common Stock owned by certain Insiders, pursuant to Stock Purchase Agreements, dated as of March 19 2026 (the “Share Redemption Agreement”) and the remainder of the proceeds shall be used for general corporate and working capital purposes. The aggregate of 6,250,000 shares consists of (i)1,500,000 shares from Dr. Glynn Wilson, the Company’s Chief Executive Officer; (ii) 1,250,000 shares from Brnan John, the Company’s Chairman; and (iii) 3,500,000 shares from NovoDX, Inc. These redemptions would reduce the total amount of shares of common stock outstanding from 14,761,925 shares to 8,511,925 shares of common stock.

The Purchaser shall have the right, exercisable at any time and from time to time, to purchase up to $4.0 million of additional shares of Series A Preferred Stock and Warrants from the Company (the AIR”), provided that any AIR may only be exercised in an amount of the AIR and shall have the same terms as the Series A Preferred Stock and Common Warrants , except that the Conversion Price and Exercise Price of the additional shares of Series A Preferred Stock and Common Warrants issued pursuant to the AIR shall be equal to the lower of (i) 90% of the arithmetic average of the five lowest closing trading prices occurring any time during the ten days prior to the Purchaser exercising an AIR pursuant to the terms of the Securities Purchase Agreement and (ii) the lowest Conversion Price and Exercise Price for any previously issued Series A Preferred Stock or Common Warrants pursuant to the Securities Purchase Agreement.

The exercise price and number of shares of Common Stock issuable upon exercise of the PIPE Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price. Subject to limited exceptions, the Purchaser may not exercise any portion of the CommonWarrants to the extent that the Investor would beneficially own more than 4.99% of the outstanding Common Stock after exercise. In the event of certain fundamental transactions, the holder of the Common Warrants A will have the right to receive the Black Scholes Value (as defined in the CommonWarrants) of its Common Warrants calculated pursuant to a formula set forth in the Common Warrants, payable in cash. There is no trading market available for the Series A Preferred Stock or Common Warrants on any securities exchange or nationally recognized trading system. The Company does not intend to list the Series A Preferred Stock or Common Warrants on any securities exchange or nationally recognized trading system.

Pursuant to the Securities Purchase Agreement, for a period of twelve (12) months after the closing date, the Purchaser shall have the right of first refusal to participate with respect to any offering involving (i) future equity or equity-linked securities of the Company or (ii) debt of the Company, which is convertible into equity or in which there is an equity component for up to 50% of any such new financing.

The securities being offered and sold by the Company in the PIPE Offering have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered shares issuable upon the conversion of the Series A Preferred Stock and the shares issuable upon exercise of the unregistered warrants pursuant to a Registration Rights Agreement entered into between the Company and the Purchaser (the “Registration Rights Agreement”).

The foregoing descriptions of the Common Warrants, Securities Purchase Agreement, Registration Rights Agreement and Share Redemption Agreement (collectively, the “Transaction Documents”), do not purport to be a complete description and are qualified in its entirety by reference to the full text of the Transaction Documents, copies of which are filed herewith as Exhibits 4.1, 10.1, 10.2, 10.3 respectively, and incorporated by reference herein.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth in Item 1.01 of this Current Report on Form 8-K with regard to the offer and sale of the shares of Series A Preferred Stock and the Common Warrants to the Purchaser pursuant to the Securities Purchase Agreement is incorporated herein by reference. The shares of Series A Preferred Stock and the Common Warrants issued and sold under the Securities Purchase Agreement as described in Item 1.01 were offered and sold by the Company in reliance upon an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

Item 3.03 Material Modification to Rights of Security Holders.

Pursuant to the PIPE Offering, on March 18, 2026, the Company filed a Certificate of Designation of Series A Convertible Preferred Stock with the Secretary of State of the State of Nevada (the “Series A Certificate of Designation”).

The stated value of the Series A Preferred Stock is $1,000 per share.

Holders shall be entitled to an 8% dividend payable in cash or shares of common stock at the holder’s option. In addition, holders shall be entitled to receive, and the Company shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.

The foregoing description of the Series A Certificate of Designation does not purport to be a complete description and is qualified in its entirety by reference to the Series A Certificate of Designation, which is filed herewith as Exhibit 3.1 and incorporated by reference into this Item 3.03.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Press Release, dated February 3, 2026
3.1		Certificate of Designation of Series A Convertible Preferred Stock
4.1		Common Stock Purchase Warrant A
10.1		Securities Purchase Agreement
10.2		Registration Rights Agreement
10.3		Form of Share Redemption Agreement
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 3, 2026	Caring Brands, Inc.
Dated: March 24, 2026	Caring Brands, Inc.
	By:	/s/ Glynn Wilson
	Name:	Dr. Glynn Wilson
	Title:	Chief Executive Officer

Filing Compare · Caring Brands, Inc.